Pharma M&A, Patent Cliffs, and Investor Concerns in Healthcare

This Reuters interview examines the wave of mergers and acquisitions in the pharmaceutical sector and whether it should concern investors, with a focus on healthcare. Leah Bennett, chief investment strategist, discusses the scale of recent dealmaking, the upcoming patent cliff, and the sector's performance relative to the broader market.

■ Deal activity and patent expirations
- $130 billion in biopharma deals in the first half of the year
- About $400 billion in drug revenue expected to lose patent protection by 2033

■ Strategic drivers and diversification
- Replacing top-selling drugs and building new pipelines
- COVID-era biotech investment, gene editing, and GLP-1 revenue concentration

■ Evaluating acquisitions and sector outlook
- 70% of pipeline drugs from emerging biopharma; high rates pressure biotechs
- Platform technologies, AI in drug discovery, and defensive healthcare demand

It is aimed at viewers interested in healthcare investing, pharmaceutical M&A, and sector strategy. Viewers gain an overview of the forces shaping pharma dealmaking and how analysts assess the sector's risks and opportunities.